GETT
17.5.2021 13:02:09 CEST | Business Wire | Press release
Gett, the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is supporting the UK government Department for Transport and its Global Travel Taskforce with the safe return of international travel.
Gett’s ground transportation B2B marketplace now provides its clients with updates from the UK Government’s ‘traffic light’ system, supporting partners and users worldwide for the safe return of international travel. On its platform, Gett will update users with information on testing, quarantining, and travel restrictions to allow passengers access to information and government guidelines in relation to the next phase of re-opening the UK economy. This initiative supports Gett’s desire to assist employers to satisfy their duty of care obligations towards their employees, by providing users with access to information for safe travel.
As announced by the UK government on 9 April 2021, the ‘traffic light’ system applies different risk-based restrictions for passengers returning to the UK. Those travelling from ‘green’ countries require a negative Covid-19 test prior to departure but do not have to isolate when coming back into the UK, whilst travellers returning from ‘amber’ countries similarly require a negative pre-departure Covid-19, but also must isolate at home for 10 days upon their return and get a PCR test on days 2 and 8. Travellers from ‘red’ countries additionally require a negative Covid-19 test prior to departure and must isolate in specified hotels for 10 days.
Currently serving more than a quarter of Fortune 500 companies, Gett‘s unique position as a B2B marketplace for ground transportation management makes Gett a valuable partner for the UK government’s reopening of corporate travel. Gett has recently strengthened its international offering, with further expansion into the US market through the continued growth of global partner fleets. This includes the previously announced partnership with e-fleet operator Curb Mobility , joining a portfolio of existing corporate fleet, ride-hailing, taxi, and limo providers, including Lyft and Ola .
Andrew Verbitsky, Deputy CEO of Gett, commented: “The safe resumption of international travel is essential to restarting the corporate travel sector and supporting and enabling global economic recovery. Gett, as the leading corporate Ground Transportation Management (GTM) platform and B2B marketplace, is uniquely positioned to be a valued partner in this important milestone for the UK and global economy. Gett is committed to the safe resumption of corporate travel for its B2B clients and their employees.”
About Gett
Gett is a technology platform solely focused on corporate Ground Transportation Management (GTM), a market worth $79.6B globally. https://bit.ly/2SEIV3M
Gett is the GTM category leader, serving over a quarter of the Fortune 500 companies.
Gett’s cloud-based software aggregates existing transportation providers onto a single platform, helping businesses manage all of their ground transportation spend. Additionally, Gett expands companies’ coverage by connecting them to a grid of transportation providers globally.
Gett organises corporate fleet, ride-hailing, taxi, and limo providers on one platform, optimising the entire employee experience, from booking and riding to invoicing and analytics, saving businesses time and money.
Founded in 2010 and headquartered in London, Gett has raised more than $750M in funding to date, including more than $300M from the Volkswagen Group.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom